An MMEX 2018 retrospective, hitting some of the high points

New Post Public Reply Private Reply Replies (0) Message Board
jmjjw
340
An MMEX 2018 retrospective, hitting some of the high points (unless one happens to be an MMEX retail “investor”):

In context, MMEX, an insolvent, super-dilutive OTC shell company, with no assets, no business operations, no employees, no suppliers, no customers, no luminary management or technical team, and no intellectual property, or proprietary technology, sits atop nearly $40-million in cumulative losses and current liabilities.

MMEX has failed, on at least five separate occasions, to close on the $49-million (initial estimate) to now $88-million in project financing to execute its proposed business plan. There are no details on the imaginary “terms sheet” from an unnamed “international debt fund,” which possibly expired on Nov. 15, 2018.

MMEX recently executed a totally botched 1-for-100 reverse split, washing out most retail “investors,” leaving them so far underwater that no recovery is possible. The reverse split took more than 60 days to execute, while Mad J., the ring-master tried to pump the share price unsuccessfully - the ex-split event was 0.0014 -> 0.14, and as predicted, MMEX retail “investors” lost during the immediate transition as their shares were not tradable. Shortly thereafter, as was predicted, and predictable, MMEX’s value decline on average by another 50% to the end of the calendar year.

The MMEX shell is set up for tight insider control, registered as a Nevada shell corporation - Nevada laws do not afford shareholder recourse, allowing the MMEX insiders complete control over the shell.

In turn, the super-dilutive equity structure insures that insiders will always have voting control, via the Class B common, which have a 10X voting preference over the Class A.

One of the most comedic 2018 events includes MMEX’s down-listing from OTCQB, back to QTC Pink - based on the failure to maintain the QB minimum bid price of 0.01 (a penny!). In that event, MMEX lost hundreds of thousands in aggregate, including access to the Crown Bridge debt deal.

MMEX failed to cure the QB listing default within six months, which now requires following the full application process, paying the QB listing fee, and application fee.

MMEX, unlike a real corporation, lacks an independent board of directors, and has no (as in zero) corporate controls or governance. This means Mad J. and The Lemon can do anything they want, like skim funds to offshore, private entities like Maple, pay themselves for things in the form of SG&A expenses and related party transactions, and even give themselves cashless options, and warrants, on free shares.

One of the fundamentals MMEX advocates fail to grasp is the nature of the scam itself.

In a real company, with corporate governance, and independent board, Mad J. would never have been hired. In the magical, mistaken condition that somehow he slipped past, he would have been fired the exact moment he proposed using floor-less, convertible toxic debt to finance a company.

MMEX is a criminal enterprise. In real companies, competent CEO’s, management teams, and boards would never allow the use of toxic debt to finance the company.

There are really only two cases where this happens: a totally incompetent CEO, lacking any competent, legitimate board, or a criminal, fraudulent insider, lacking any board control. That’s it. There is no grey area.

Anyone who “invested” in MMEX has been scammed - their money stolen. The MMEX scam is coming unwound at the seams.

MMEX Resources Corporation (MMEX) Stock Research Links

MMEX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 6

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 3

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 6

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 7

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 21

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 7

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 6

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 6

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading

Top 5 Most Recently Viewed Articles

Investing Insights: Man Group PLC's Position in Spectris plc

Updated Category News Views 315

Understanding Man Group PLC's Investment Position Man Group PLC, a primary player in investment management, recently announced its public interests regarding relevant securities in Spectris plc. This disclosure highlights its strategic investment and positions in the market. Key Information Disclosure As per regulatory requirements, Man Group PLC has provided essential...

Continue Reading
Coca Cola Surpasses Expectations Amidst Market Challenges

Updated Category News Views 357

Coca Cola Surpasses Expectations Amidst Market Challenges On a recent earnings announcement, The Coca Cola Company (NYSE: KO) exceeded Wall Street predictions, showcasing a resilient strategy to enhance revenue and earnings despite shifting consumer preferences. While demand for beverages has softened, Coca Cola's ability to raise prices proved beneficial, even as...

Continue Reading
Joget Enhances Application Development Using AI and Security

Updated Category News Views 86

Transforming Application Development with Joget AI The innovative Vibe Composition approach by Joget empowers enterprises to craft robust applications by utilizing trusted, composable components rather than traditional raw coding methods. This modern take on application development is encapsulated within the Joget AI Designer, making the process both efficient and secure....

Continue Reading
Gimme Credit Unveils Innovative Platform to Enhance Global Research

Updated Category News Views 215

Introducing Gimme Credit's New Client Platform Gimme Credit, a prominent independent provider of credit research and data, has recently launched a cutting-edge delivery platform. This initiative marks a significant step in the company's global expansion and innovation efforts. An Era of Growth and Technological Innovation The new platform utilizes a cloud-based...

Continue Reading
Comprehensive Overview of SCOR's Share and Voting Rights Data

Updated Category News Views 36

Understanding SCOR's Share Capital and Voting Rights In today's competitive landscape, it is crucial for companies to maintain transparency regarding their operations and shareholder information. SCOR, a notable player in the global reinsurance market, has recently provided an insightful declaration concerning its share capital and voting rights. This information...

Continue Reading